
Blue Star Q2: One-Off Gain Lifts Consolidated PAT 25%, Standalone Profit Halves YoY
Blue Star's consolidated Q2 FY27 revenue rose 21.0% YoY to ₹2,930.95 Cr (down 13.2% QoQ, tracking the Unitary segment's seasonal slowdown after the summer peak), and reported PAT rose 25.4% YoY to ₹123.91 Cr. That headline is flattered by a ₹23.02 Cr exceptional gain the Group booked on the completed sale of subsidiary Blue Star Engineering & Electronics' Medtech business; stripping it out (at the quarter's ~21% effective tax rate), adjusted PAT grew only about 7% YoY to roughly ₹106 Cr — well behind revenue growth and the clearer signal that underlying profitability is still under pressure. The compression sits almost entirely in the Unitary Products segment (room ACs and commercial refrigeration): EBIT margin was just 2.31% (₹20.74 Cr on ₹897.66 Cr revenue) against the >6.5% FY27 target (aspiring 7-7.5%) management set out on the August 13, 2026 concall, barely improved from Q1 FY27's 2.94% — exactly the input-cost and pricing pressure the segment has been flagged for since Q1. The Electro-Mechanical Projects & Commercial AC segment is the quarter's carrier: margin 6.88%, inside the guided 6.5-7% band, on revenue up 16.3% YoY to ₹1,935.99 Cr. Blended consolidated operating margin came to 6.91%, down from 7.57% a year ago though up sequentially from Q1's 5.18%. The parent-only (standalone) numbers tell a materially different story than consolidated and are worth flagging explicitly: standalone PAT fell 45.3% YoY to ₹38.24 Cr (from ₹69.91 Cr), standalone operating margin compressed to 4.24% from 5.97%, and standalone NPM to 1.39% from 3.03% — consolidated profit growth this quarter is a subsidiary-and-one-off story, not a core-business one. Against our pre-result preview (consolidated revenue ₹3,200-3,400 Cr, EBITDA margin 5.5-6.0%, net profit ₹85-110 Cr), the print is mixed: revenue missed the range, operating margin beat it, and adjusted PAT (~₹106 Cr) landed near the top of the band — a scorecard closer to inline than a clean beat once the one-off is excluded. No standalone management press release accompanied this filing beyond the regulatory board-outcome letter, so there is no additional management framing to reconcile against the numbers; the quarter's other disclosed developments — the completed Medtech divestment (up to ₹40 Cr) and the dismissal of WJT's Oman arbitration claims against the company (September 15, 2026) — are already reflected in or neutral to the P&L. Management's prior tone (cautiously optimistic outlook, cautious posture per the August concall) is consistent with a quarter where the flagged margin risk in Unitary Products continued to play out rather than reverse.
Key Highlights
- Consolidated revenue ₹2,930.95 Cr (+21.0% YoY, -13.2% QoQ on Unitary seasonality); PAT ₹123.91 Cr (+25.4% YoY) — but adjusted for a ₹23.02 Cr one-off, PAT growth is only ~+7% YoY.
- ₹23.02 Cr exceptional gain from the completed Medtech business sale by subsidiary Blue Star E&E inflates the reported bottom line this quarter.
- Standalone (parent) PAT fell 45.3% YoY to ₹38.24 Cr (from ₹69.91 Cr), with standalone OPM down to 4.24% from 5.97% and NPM to 1.39% from 3.03% — a sharply different story from consolidated.
- Unitary Products segment EBIT margin just 2.31% (₹20.74 Cr on ₹897.66 Cr revenue) vs management's FY27 target of >6.5%, barely improved from Q1's 2.94%.
- Electro-Mechanical Projects & Commercial AC segment margin 6.88% — within the 6.5-7% guided band — on revenue up 16.3% YoY to ₹1,935.99 Cr, carrying the quarter.
- Consolidated operating margin 6.91%, down from 7.57% a year ago; EPS ₹6.03 basic vs ₹4.80 YoY and ₹4.99 in Q1.
Price Impact
More from BLUESTARCO